Uveitis
📧 Sign up to get email alerts when something new happens for Uveitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Results: Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing [NA]
Clinical trial results investigating ocular pathogens and transcriptome using comprehensive sequencing in uveitis and infectious disease.
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Intestinal Bacteria and Ocular Inflammatory Disease
A completed clinical trial investigating the relationship between intestinal bacteria and uveitis (ocular inflammatory disease) conducted by…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis. [Phase 2]
A Phase 2 trial evaluating the efficacy and safety of GenSci048 in active uveitis is not yet recruiting. The sponsor is Changchun GeneScienc…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Uveitis in Children <18 Years of Age
A pediatric uveitis clinical trial sponsored by Jaeb Center for Health Research is currently recruiting participants under 18 years of age.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
NEI-sponsored Uveitis/Intraocular Inflammatory Disease Biobank (iBank) clinical trial has completed.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
A pediatric non-infectious chronic uveitis trial (RChildUV) is currently recruiting, sponsored by Meyer Children's Hospital IRCCS.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Imaging Quantification of Inflammation (IQI)
An ongoing clinical trial called Imaging Quantification of Inflammation (IQI) for uveitis is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
The Cleveland Clinic is conducting a clinical study to analyze anterior chamber inflammation in uveitis using optical coherence tomography, …
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Genetics of Uveitis
A Cleveland Clinic–led clinical trial examining the genetics of uveitis is currently recruiting.
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-16EMA Authorised: Hefiya (adalimumab) — Sandoz GmbH
EMA authorised Hefiya, a biosimilar adalimumab from Sandoz GmbH, for multiple inflammatory conditions including ankylosing spondylitis, hidr…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant
This clinical trial update summarizes imaging findings in uveitis patients treated with the fluocinolone acetonide intravitreal implant (ILU…
-
EMA approval · 2026-02-04EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondyli…
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
The study evaluated switching patients from original infliximab to its biosimilar in daily practice at Cochin Hospital, across rheumatoid ar…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis [Phase 3]
A Phase 3 clinical trial update for Brepocitinib in adults with active, non-infectious, non-anterior uveitis, with the study currently activ…